Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT03705806

Palliative Thoracic ImmunoRT

Evaluation of Toxicities With Thoracic Radiotherapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
12 (actual)
Sponsor
University Health Network, Toronto · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.

Conditions

Interventions

TypeNameDescription
RADIATIONRadiation combined with immunotherapyThe trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.

Timeline

Start date
2018-10-03
Primary completion
2027-09-01
Completion
2027-09-01
First posted
2018-10-15
Last updated
2026-03-04

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03705806. Inclusion in this directory is not an endorsement.